Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

Affiliations

• ¹ Department of Hematology and Oncology, Ulsan University Hospital, Bangeojinsunhwando-ro, Dong-gu, Ulsan, 877, Korea. sujinkoh@uuh.ulsan.kr.
• ² Department of Breast Oncology, NHO Shikoku Cancer Center, Ehime, Japan.
• ³ Department of Breast Surgery, NHO Hokkaido Cancer Center, Hokkaido, Japan.
• ⁴ Breast Center, Kameda Medical Center, Chiba, Japan.
• ⁵ Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
• ⁶ Department of Breast and Endocrine Surgical Oncology, Tohoku University Hospital, Miyagi, Japan.
• ⁷ Tri-Service General Hospital, Taipei, Taiwan.
• ⁸ Cheng Hsin General Hospital, Taipei, Taiwan.
• ⁹ AstraZeneca Pharmaceuticals, Gaithersburg, USA.
• ¹⁰ AstraZeneca, Cambridge, UK.
• ¹¹ Baylor Charles A. Sammons Cancer Center, Texas, USA.
• ¹² Hospital Universitari Vall d'Hebron, Barcelona, Cataluña, Spain.